MOTS-c vs SS-31
MOTS-c has human biomarker studies and a native Phase 2 registration without a cited result. SS-31 (elamipretide) has human trials and product-specific FDA accelerated approval for Barth syndrome, with confirmatory benefit pending.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
MOTS-c
Dossier overview
SS-31
Dossier overview
Different clinical status
MOTS-c is a mitochondrial 12S-region peptide examined in metabolic and physical-capacity models. SS-31, also called elamipretide, is a synthetic cardiolipin-binding tetrapeptide with indication-specific clinical trials. A product approval for one condition does not validate either peptide for longevity. MOTS-c discovery, PMID 25738459 · SS-31 mechanism, PMID 23813215
| Evidence question | MOTS-c | SS-31 / elamipretide |
|---|---|---|
| Human intervention | Native Phase 2 registration; no cited efficacy or safety result | Published controlled trials in defined diseases |
| US regulatory status | No FDA-approved native MOTS-c medicine verified | Forzinity received accelerated approval for Barth syndrome patients weighing at least 30 kg |
| Human-evidence status | Endogenous observations and a native Phase 2 registration without cited results | Forzinity has product-specific accelerated Barth approval, with patient benefit awaiting confirmation; the primary-mitochondrial-myopathy trial missed both primary endpoints |
Human MOTS-c exercise, sleep-apnea and diabetes studies measured endogenous peptide; mouse experiments tested administered MOTS-c. A 2026 C26 mouse/cell cachexia paper found partial preservation of skeletal muscle after preventive exposure, without preventing overall body or fat loss and without a human treatment arm. PMID 33473109 · PMID 40538389 · PMID 40855115 · PMID 42266945
NCT07505745 registers native MOTS-c for adults with prediabetes and overweight or obesity, but no outcome is cited in the accepted review. NCT03998514 concerns CB4211, a separate analog, and cannot supply native MOTS-c results.
FDA granted accelerated approval on September 19, 2025 to the specific Forzinity product to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg. Its intermediate endpoint was knee-extensor strength and a confirmatory trial is required to verify patient benefit. The 12-person randomized Barth crossover phase missed its two prespecified primary endpoints; FDA says the knee-strength increase was seen in the later open-label extension, not during the randomized phase. The extension and natural-history comparisons have design limits. This is regulatory and study status, not a confirmed general efficacy grade. FDA announcement · FDA trial snapshot · Barth trial, PMID 33077895
The 218-person MMPOWER-3 randomized trial in primary mitochondrial myopathy missed both primary endpoints at 24 weeks. Thus the Barth approval cannot be generalized to that disease, heart failure, retinal disease, or exercise enhancement. MMPOWER-3, PMID 37268435
The Forzinity label describes product-specific hypersensitivity and injection-site risks; it does not establish safety of unrelated preparations. FDA says compounded MOTS-c exposure information is insufficient. No head-to-head MOTS-c/elamipretide study is cited. FDA Forzinity label · FDA compounding safety review
This comparison is for research literacy, not use outside an approved indication.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.